Contracts › 75F40126C00123
75F40126C00123: Eo 14398 - Medical Device Companies Fail at Rates Up to 75% (Falahat & Falahat, 2024). Across 13 Years of Evaluating 14,000+ Companies, Mti Has Documented a Consistent Cause: Fda Market Authorization Is Necessary But Rarely Sufficient. Innovators
Awarded to Medtech Innovator by Food and Drug Administration (FDA).
$1.9Mobligated
$2.0Mpotential value
29 September 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40126C00123 |
|---|---|
| Awardee | Medtech Innovator |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541990 All Other Professional, Scientific, and Technical Services |
| PSC | R408 Support- Professional: Program Management/Support |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 30 September 2026 to 29 September 2028 |
| Potential end | 29 September 2028 |
| Estimated recompete solicitation | ~Q2 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 12 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541990 contracts · All expiring contracts · USASpending record